PubMed Health⌕ Search

Biomedical subjects

F Feng

Publications and source records attributed to F Feng.

At least 37 records · Page 2Linked to original sources
PubMed1999

[Expression of multidrug resistance-associated protein in human non-small cell lung cancer].

OBJECTIVE: To investigate the expression of the multidrug resistance-associated protein(MRP) gene and MRP in human non-small-cell lung cancer tissues and to determine whether such expression was related to cell type, differentiation, tumour size, lymph node metastasis and prognosis. METHODS: 92 paraffin-embeded lung tumor samples (43 squamous cell carcinoma, 49 adenocarcinoma) and 16 fresh non-small-cell lung cancer samples were examined by using immunohistochemistry method and the reverse transcription-polymerase chain reaction (RT-PCR) technology respectively. RESULTS: The expression of MRP mRNA and MRP were detectable in 31% (5-16) and 54% (50/92) of non-small-cell lung cancer specimens respectively. Eighteen(42%) squamous cell carcinoma specimens and thirty-two(65%) adenocarcinoma specimens showed positive immunostaining for MRP(P < 0.05). The expression of MRP was not related to tumour size, lymph node metastasis and cell differentiation significantly(P > 0.05). The five-year survival rate after operation of patients with MRP-positive tumours and MRP-negative tumours were 16% (8/50), 52% (22/42) respectively. Patients with MRP-positive tumours had shorter survival time than the MRP-negative patients significantly(P < 0.01). CONCLUSIONS: Adenocarcinoma had higher MRP expression than squamous carcinoma significantly, positive MRP immunostaining appears to be an independent indicator of poor prognosis in NSCLC.

Adult↗
PubMed1999

[Clinical study of anastrozole in the treatment of postmenopausal women with advanced breast cancer].

OBJECTIVE: To study the effect and adverse reactions of anastrozole in the treatment of postmenopausal women with advanced breast cancer. METHODS: A multicenter, open, non-randomized and crossover clinical trial on the effect of anastrozole was conducted. Sixty-one postmenopausal women with advanced breast cancer were treated by oral anastrozole, 1 mg once every day. Each patient received 4-6 weeks of treatment. Plasma estradiol concentrations were determined 2 weeks before treatment and within 3 days after treatment discontinued. Effect and adverse reaction were evaluated. RESULTS: The response rate in 60 evaluable cases treated with anastrozole was 21.7% (CR = 0, PR = 13, MR = 2). The effect was correlated with postmenopausal time, previous endocrine therapy and ER status. Plasma level of estradiol was suppressed by 58.3%. The main adverse reactions, including nausea, fatigue, facial flush, were generally tolerable. CONCLUSION: As an aromatase inhibitor capable of decreasing plasma estradiol level, anastrozole is therapeutically effective for advanced breast cancer in postmenopausal women. Side effects are mild and tolerable.

Adult↗
PubMed1999

[Expression of multidrug resistance-associated protein (MRP) and lung resistance protein (LRP) in human rectal carcinomas and its clinical significance].

OBJECTIVE: To investigate the expression and clinical significance of multidrug resistance-associated protein(MRP) and lung resistance protein(LRP) in rectal carcinoma. METHODS: Fiftyseven paraffin embeded primary rectal carcinoma specimens were examined by immunohistochemical staining. RESULTS: Of the 57 tumour specimens examined, 28(49.1%) and 24(42.1%) were positively immunostaned for MRP and LRP, respectively. Co-expression of the two proteins was observed in 10(17.5%) specimens. Positive immunostaning of either of the two proteins was not correlated with cell differentiation and Dukes stage (P > 0.05). Patients with MRP-positive tumours had shorter survival than MRP-negative patients (P < 0.05). No such correlation was found for LRP expression, nor was found between MRP and LRP expression. CONCLUSION: Positive MRP expression in rectal carcinoma appears to be an independant factor of prognostic significance. To examine its expression may help guide rational comprehensive therapy of rectal carcinoma.

Adult↗
PubMed1999

[Mitomycin, vindesine and cisplatin combination therapy in the treatment of advanced non-small cell lung cancer: a report of 108 cases].

OBJECTIVE: To evaluate the results of combination chemotherapy with mitomycin (MMC), vindesine (VDS) and cisplatin (DDP) in patients with advanced non-small cell lung cancer (NSCLC). METHODS: A total of 108 patients with advanced NSCLC was enrolled in this study. Adenocarcinoma (74 cases) and squamous-cell carcinoma (23 cases) were the most common type of malignancy. Thirty patients received prior chemotherapy while 78 did not. RESULTS: Complete response was observed in 1 patient and partial response in 36 patients with an overall response rate (RR) of 34.3%. The RR was significantly higher in the previously untreated patients (41.0%) and than that in the pretreated patients (P = 0.0169). The RR did not significantly differ between patients with squamous--cell carcinoma (30.4%) and adenocarcinoma (32.4%). That of patients with metastases to the lymph nodes, to the other parts of lung, liver and bone was 43.1%, 32.4%, 25.0% and 0, respectively. The median response duration was 3 months and the median survival period was 7 months. The dose limiting toxicity was neutropenia, which was in grade III and IV in 41.7% of the treated patients. Grade III and IV thrombocytopenia was observed in 6.5% and grade III and IV nausea and vomiting in 21.3% of the treated patients. CONCLUSION: A higher response rate is attainable in patients with advanced NSCLC treated by MMC, VDS and DDP with tolerable toxicity.

Adult↗
PubMed1999

[Phase II clinical study of a new anticancer drug boanmycin].

OBJECTIVE: To evaluate the efficacy of boanmycin (BAM) in patients with advanced cancers. METHODS: A multicenter phase II clinical study on BAM was conducted on 105 cases received BAM as single agent, and 220 cases were treated with combination chemotherapy containing BAM. RESULTS: The total response rate was 35.0% for single agent and 64.2% for combination chemotherapy group in advanced cancers. The response rate for single agent in malignant lymphoma, cancer of head and neck and breast cancer was 66.7%, 65.0% and 37.5%, respectively; and for combination chemotherapy group in malignant lymphoma, breast cancer, head and neck cancer, esophageal cancer and lung cancer was 88.5%, 62.5%, 50.0%, 47.2% and 45.8%, respectively. The main side effects with mild or moderate fever, chill, myalgia, gastrointestinal reactions, skin pigmentation as well as hardening of skin at injection site. CONCLUSIONS: BAM therapy was effective in malignant lymphoma, cancer of head and neck and other cancers.

Adolescent↗
PubMed1998

Detection of mouse osteopontin by western blotting.

Several different antibodies to mouse and/or rat osteopontin have been developed, and some antisera raised against human osteopontin have been shown to react with mouse osteopontin. We have taken advantage of the lack of osteopontin protein in mice with a targeted disruption of the osteopontin gene to characterize the reactivity and the specificity of several of these antibodies with mouse osteopontin by Western blotting. Our results demonstrate that, with the exception of the rat monoclonal antibody MPIIIB10, which does not recognize mouse osteopontin on Western blots, all the tested reagents do react with mouse osteopontin, but their sensitivity varies widely, and in some cases there is significant cross-reactivity of the antibodies with other proteins found in mouse tissue extracts.

Animals↗
PubMed1998

Electrical impedance tomography reconstruction algorithm based on general inversion theory and finite element method.

A strict EIT reconstruction algorithm, the general inversion algorithm (GIA) is presented. To improve the noise performance, the algorithm is modified by attenuating the condition number of the forward matrix F and implemented using an improved FEM scheme, to obtain the 2D image of impedance change (dynamic image). This modified general inversion algorithm (MGIA) can be used on a larger dimension FEM model (248 elements) and is more practical than the GIA. When implementing this algorithm in computer simulation and in a physical phantom, it is found that the MGIA has a smaller reconstruction error than the currently used algorithms (equipotential-back-projection algorithm and filtered spectral expansion algorithm). With 0.1% white noise in the data, the algorithm can still reconstruct images of a complicated model. Further improvements are also discussed.

Algorithms↗
PubMed1998

Comparison of radiography, computed tomography and magnetic resonance imaging in the detection of sacroiliitis accompanying ankylosing spondylitis.

OBJECTIVE: To compare magnetic resonance (MR) imaging, computed tomography (CT), and radiography in the detection of sacroiliitis accompanying ankylosing spondylitis (AS). DESIGN AND SUBJECTS: Nine volunteers and 24 patients were recruited. Radiography, CT, and MR imaging were completed within a 1-week period in 24 patients with AS. In precontrast MR examination, spin-echo T1, fast spin-echo T2, and gradient echo with rephasing T2* images were obtained without fat saturation using a 0.3-T imager for all volunteers and patients. Postcontrast MR examination was performed using the same precontrast SE T1 sequence for patients with AS. RESULTS AND CONCLUSIONS: MR imaging directly showed the normal cartilage in all 16 sacroiliac joints of the 8 volunteers. In the 24 patients with AS, cartilage abnormalities were observed in 42 sacroiliac joints. More diagnoses of sacroiliitis were made using MR and CT imaging than using radiography (P < 0.001). Therefore, low-field-strength MR can be useful in detecting early sacroiliitis in patients with AS. MR imaging was able to reveal early cartilage changes and bone marrow edema, which could not be found by either CT or radiography.

Adolescent↗
PubMed1998

Association of a serotonin transporter gene promoter polymorphism with harm avoidance behaviour in an elderly population.

A polymorphic 44-nucleotide insertion/deletion in the promoter region of the serotonin transporter gene (5-HTTLPR) has been shown to affect the level of expression of the serotonin transporter protein. An association between anxiety-related behavioural traits and the short form of the 5-HTTLPR has been reported. We determined the 5-HTTLPR genotype in genomic DNA samples from 84 subjects (47 Parkinson's disease patients and 37 controls) with a mean age of 67.4 years. The TPQ of Cloninger was used to obtain values for harm avoidance (HA), reward dependence and novelty seeking for all subjects. Analysis of variance showed a significant influence of the s-allele of the 5-HTTLPR on HA in both subject groups, with no significant interaction between diagnosis and genotype. Subjects with the l/l-genotype had significantly lower mean HA scores than the l/s subjects (P < 0.04) and s/s subjects (P < 0.003). A linear change in HA with genotype was observed, indicating a gene dose effect of the 5-HTTLPR s-allele on this personality dimension. Based on these findings it is suggested that there may be increased influence of the 5-HTTLPR short allele on anxiety-related traits during aging.

Aged↗
PubMed1998

Association of long variants of the dopamine D4 receptor exon 3 repeat polymorphism with Parkinson's disease.

The dopamine D4 receptor (D4DR) has a highly polymorphic region in the third exon which has been associated with novelty seeking (NS) behavior. Due to the central position of dopamine and the documented low NS in Parkinson's disease (PD), the frequency of the exon 3 variants of D4DR in 95 PD patients and 47 controls was investigated. A significantly higher frequency of exon 3 alleles with six or more repeat units was found in the PD group (p = 0.039). This provides evidence that some forms of the highly polymorphic D4DR may represent a genetic susceptibility factor for PD.

Adult↗
PubMed1998

[Randomized controlled study of leucomax (recombinant human granulocyte-macrophage colony stimulating factor, rhGM-CSF) in the treatment of cancer chemotherapy-induced leucopenia].

OBJECTIVE: To evaluate leucomax (rhGM-CSF) in prevention and treatment of leucopenia and neutropenia induced by chemotherapy in cancer patients. METHODS: A multicenter, randomized, matched and cross-over clinical trial of the effect of leucomax on leucopenia and neutropenia induced by combination chemotherapy in cancer patients was conducted. Fifty seven enrolled patients were randomized into AB group and BA group. Each patient received two cycles of treatment. In group AB, combination chemotherapy and leucomax were used in the first cycle and combination chemotherapy alone was used in the second cycle, while vice versa in group BA. In 2 patients, the study was stopped due to leucomax adverse reactions. Fifty five patients were eligible for analysis of clinical efficacy. RESULTS: Leucomax significantly increased the number of total white blood cell count and absolute neutrophil count at the nadir, decreased the incidence of leucopenia and neutropenia and shortened the time period of leucopenia and neutropenia induced by chemotherapy. Leucomax also resulted in quicker recovery of leucopenia and neutropenia. Leucomax ensured the scheduled chemotherapy. The main adverse reactions with mild to moderate fever, pain at the injection site, bone pain, myalgia, asthenia and skin rash were generally tolerable. CONCLUSION: Leucomax is a valuable adjunct in cancer chemotherapy.

Adult↗
PubMed1998

[Molecular cloning and DNA sequencing of OspC gene of two strains Borrelia burgdorferi isolated in China].

OBJECTIVE: To investigate the variation of OspC gene in two Chinese isolates of Borrelia burgdorferi. METHODS: PCR technique was used to amplify the OspC gene from the whole cellular DNA of isolates BT01 and BJ-9011. The amplified products were inserted into plasmid pGEM-3ZF(+) and sequenced. RESULTS: Except the signal peptide, the OspC genes of the two isolates BT01 and BJ-9011 were 579 bp and 576 bp which encode 193, 192 amino acids respectively. The nucleotide and amino acids sequence identity between the two strains was 86% and 83%. High homology exists between these Chinese isolates and several foreign isolates (PBi, PKo, B31), especially in BJ-9011. It had 99% nucleotide and amino acid sequence identified with B31. CONCLUSION: Variations in OspC genes are noted between the two Chinese Borrelia burgdorferi isolates and foreign isolates.

Antigens, Bacterial↗
PubMed1997

Subtype-specific intracellular trafficking of alpha2-adrenergic receptors.

The three alpha2-adrenergic receptor subtypes (alpha2a, alpha2b, and alpha2c) are highly homologous G protein-coupled receptors. These receptors all couple to pertussis toxin-sensitive G proteins and have relatively similar pharmacological properties. To further explore functional differences between these receptors, we used immunocytochemical techniques to compare the ability of the three alpha2-receptor subtypes to undergo agonist-mediated internalization. The alpha2a-receptor does not internalize after agonist treatment. In contrast, we observed that the alpha2b-receptor is able to undergo agonist-induced internalization and seems to follow the same endosomal pathway used by the beta2-adrenergic receptor. Attempts to examine internalization of the alpha2c-receptor were complicated by the fact that the majority of the alpha2c receptor resides in the endoplasmic reticulum and cis/media Golgi and there is relatively little cell surface localization. Nevertheless, we were able to detect some internalization of the alpha2c-receptor after prolonged agonist treatment. However, we observed no significant movement of alpha2c-receptor from the intracellular pool to the plasma membrane during a 4-hr treatment of cells with cycloheximide, suggesting that these cells are unable to process alpha2c-receptors in the same way they process the alpha2a or alpha2b subtypes.

Amino Acid Sequence↗
PubMed1997

[Comparison of radiographs and magnetic resonance imaging in the detection of sacroiliitis in patients with ankylosing spondylitis].

The role of radiography and magnetic resonance (MR) imaging in the detection of sacroiliitis in patients with ankylosing spondylitis (AS) was compared in this study. Thirty-six sacroiliac joints in 18 patients with AS were examined with radiography and MR scan. MR images were performed with the sequence of the coronal T1 weighted image, T2 weighted image, and T2* weighted image. Images of all patients were graded according to the modified New York criteria. Statistical results showed that significant differences existed between MR imaging and radiography in the detection of sacroiliitis (P < 0.01). MR imaging was superior to plain film radiographs in visualising erosions (P < 0.01). Radiography cannot reveal the cartilage changes and bone marrow oedema, which can only be seen in MR images. In the absence of radiographic changes, MR imaging can provide objective and complementary findings of sacroiliitis in patients with AS. Due to the ability to image cartilage changes and bone marrow oedema directly, MR imaging may be particularly useful in early diagnosis of sacroiliitis. For patients without any changes on sacroiliac joint radiograph, further examination of MR imaging may be advisable.

Adolescent↗
PubMed1997

Expression of HBV Pre S1 peptide in E. coli and product characterization.

HBV Pre S1 sequence is supposed to play an important role in the infection of HBV. Presence of Pre S1/anti-Pre S1 in serum has valuable clinical implications. In order to improve the study of Pre S1, Pre S1 sequence was overexpressed in E. coli as a fusion protein with MBP (Maltose-binding protein), and anti-Pre S1 antiserum was elicited in rabbits by Pre S1-MBP purified by affinity chromatography. The recombinant plasmid constructed from pMAL-cRI expressed the 106aa Pre S1 sequence at the C terminal of MBP by tac promoter. The resulting protein is about 54 kD in size. Western-blot analysis confirmed its reactivity with antiserum derived from synthetic Pre S1 peptide and serum from patients with acute hepatitis B (AHB). ELISA showed that Pre S1-MBP and Dane particles purified from AHB patient's serum reacted with antiserum against synthetic Pre S1 peptide, and this reaction was specifically inhibited by synthetic Pre S1 peptide. ELISA also demonstrated that antiserum against Pre S1-MBP reacted with synthetic Pre S1 peptide, but not with synthetic HCV peptide or HEV peptide.

Escherichia coli↗
PubMed1996

Artificial neural network to assist psychiatric diagnosis.

BACKGROUND: Artificial Neural Network (ANN), as a potential powerful classifier, was explored to assist psychiatric diagnosis of the Composite International Diagnostic Interview (CIDI). METHOD: Both Back-Propagation (BP) and Kohonen networks were developed to fit psychiatric diagnosis and programmed (using 60 cases) to classify neurosis, schizophrenia and normal people. The programmed networks were cross-tested using another 222 cases. All subjects were randomly selected from two mental hospitals in Beijing. RESULTS: Compared to ICD-10 diagnosis by psychiatrists, the overall kappa of BP network was 0.94 and that of Kohonen was 0.88 (both P < 0.01). In classifying patients who were difficult to diagnose, the kappa of BP was 0.69 (P < 0.01). ANN-assisted CIDI was compared with expert system assisted CIDI (kappa = 0.72-0.76); ANN was more powerful than a traditional expert system. CONCLUSION: ANN might be used to improve psychiatric diagnosis.

Adult↗
PubMed1996

[Phase I clinical study of a new anticancer drug boanmycin].

From August 1993 to March 1994, 36 patients were enrolled for a phase I study of Boanmycin (Bleomycin A6) a new anticancer drug to determine it toxicity and maximal dose. Of the 36 cases, 16 were male and 20 female, age 20-62. Dose escalation was performed if a minimum of threed patients were fully evaluable for toxicity (2 weeks following drug administration) and if severe or life-threatening toxicity had not occurred. Dose of Boanmycin were escalated from 1 mg (0.5-0.7 mg/m2) to 12 mg(6.7-7.5 mg/m2) i. m. three times every week for two weeks. Surveillance of serum concentration of Boanmycin was conducted in six cases by microbiological analysis, and the pharmacokinetics parameters were obtained. Phase I study of Boanmycin showed that Boanmycin had no myelosuppression and cardiac toxicity, and its major adverse reactions were fever, gastrointestinal reactions and hardening at injection (by i. m. route). Rather than dose-related, fever was individual-related. There were mild myalgia, alopecia, skin rash, pigmentation in some patients. All adverse reactions resolved after discontinuation of therapy. There was no Boanmycin-related lethal complication, and the maximum tolerated dose was not obtainable. If patients have renal or lung disease, Boanmycin aggravate their renal and lung functions. Therefore we recommend that dose of Boanmycin for phase I clinical trial should be is 8-10 mg(5-6 mg/m2) i m or iv (iv can decrease local side effect) two-three times per week.

Adult↗